A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of SIM0811 Injection in Healthy Chinese Adult Subjects

NCT07345364 | Not Yet Recruiting Phase 1

• 1 other identifier: SIM0811-101
• Study Type: interventional
• Target: 56
• Locations: 1 country
• Sites: 1

Brief Summary

This study plans to set up 5 dose groups across 7 cohorts, including intravenous bolus plus infusion administration as well as intravenous bolus alone. The study plans to enroll 8 subjects per cohort (investigational drug: placebo = 6:2), including both males and females, totaling 56 healthy subjects. The study begins with dose-escalation enrollment starting from Cohort 1. Each cohort receives a single dose, sequentially completing Cohorts 2, 3, 4, 5, 6, and 7. After each cohort's dosing is completed, a 7-day observation period is conducted for safety evaluation. If the termination criteria are not met, the study may proceed to the next dose level following assessment by the Safety Review Committee. By collecting adverse events, as well as abnormal indicators from vital signs, electrocardiograms, and laboratory tests, and collecting blood samples at planned time points to measure SIM0811 plasma concentration and thrombotic molecular markers, the study aims to evaluate the tolerability and safety of SIM0811 injection in Chinese healthy adult subjects, characterize its pharmacokinetic profile after single-dose administration, and explore the change curves of thrombotic molecular markers (plasmin-α2 antiplasmin complex PIC, fibrin degradation products FDP)

Conditions

Health, Subjective

Outcome Measures

Primary Outcomes (1)

• Adverse events (AEs), including type, incidence, grade (assessed according to NCI-CTCAE V5.0 criteria)

  7 days after final dose

Secondary Outcomes (4)

• Peak plasma concentration(Cmax) of SIM0811 in serum

  Within 1-2 weeks of final blood sample collection

• Area Under the Concentration-time Curve from Time 0 to Time t of SIM0811 in serum

  Within 1-2 weeks of final blood sample collection

• Area Under the Concentration-time Curve from Time 0 to Infinity of SIM0811in serum

  Within 1-2 weeks of final blood sample collection

• Elimination Half-Life (T1/2) of SIM0811 in serum

  Within 1-2 weeks of final blood sample collection

Study Arms (2)

SIM0811

EXPERIMENTAL

The study is designed to include 5 dose groups across 7 cohorts, with two administration methods: intravenous bolus plus intravenous infusion, and intravenous bolus alone. Each cohort will enroll 6 subjects to receive SIM0811 The study will employ a dose-escalation design starting from Cohort 1. After administration in each dose group/cohort, subjects will be observed for 7 days for safety evaluation. Provided no stopping criteria are met, escalation to the next dose level may proceed only after review by the Safety Review Committee (SRC)

Drug: SIM0811

Placebo

PLACEBO COMPARATOR

The study is designed to include 5 dose groups across 7 cohorts, with two administration methods: intravenous bolus plus intravenous infusion, and intravenous bolus alone. Each cohort will enroll 2 subjects to receive placebo The study will employ a dose-escalation design starting from Cohort 1. After administration in each dose group/cohort, subjects will be observed for 7 days for safety evaluation. Provided no stopping criteria are met, escalation to the next dose level may proceed only after review by the Safety Review Committee (SRC)

Drug: Placebo

Interventions

SIM0811 DRUG

The study will employ a dose-escalation design starting from Cohort 1. Each cohort will receive a single administration, sequentially completing Cohort 2, Cohort 3, Cohort 4, Cohort 5 , Cohort 6, and Cohort 7. After administration in each cohort, subjects will be observed for 7 days for safety evaluation. Provided no stopping criteria are met, escalation to the next dose level may proceed only after review by the Safety Review Committee (SRC).

SIM0811

Placebo DRUG

The study will employ a dose-escalation design starting from Cohort 1. Each cohort will receive a single administration, sequentially completing Cohort 2, Cohort 3, Cohort 4, Cohort 5 , Cohort 6, and Cohort 7. After administration in each cohort, subjects will be observed for 7 days for safety evaluation. Provided no stopping criteria are met, escalation to the next dose level may proceed only after review by the Safety Review Committee (SRC).

Placebo

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy Chinese male or female adults aged 18 to 45 years (inclusive), not pregnant and not breastfeeding.
• Male subjects weight ≥50 kg, female subjects weight ≥45 kg, all ≤90 kg. Body Mass Index (BMI) between 19 and 26 kg/m² (inclusive). BMI = weight (kg) / height² (m²).
• Female subjects must avoid the menstrual period during the trial. Subjects of childbearing potential must commit to no plan for pregnancy, sperm/egg donation within 2 weeks before screening and for 6 months after the last dose, and voluntarily adopt highly effective contraception (including partner).
• Able to complete the study according to protocol requirements and commit to abstaining from smoking and alcohol during the trial.
• Prior to the trial, have fully understood the nature, significance, potential benefits, possible inconveniences, and potential risks of the trial, voluntarily participate, can communicate well with the investigator, comply with all study requirements, and voluntarily sign the Ethics Committee-approved Informed Consent Form.

You may not qualify if:

• Subjects meeting any of the following criteria will be excluded:
• History of drug allergy, or specific allergies (asthma, urticaria, eczema, etc.), or allergic constitution (e.g., allergy to two or more drugs, foods, pollen), or known allergy or significant intolerance to the investigational product or any of its components.
• Presence of clinically significant history of cardiovascular, respiratory, endocrine, urinary, digestive, hematological, neurological, skin, malignant tumor, infectious diseases, psychiatric disorders (e.g., seizures), metabolic abnormalities/dysfunction, etc.
• Screening physical examination, vital signs, laboratory tests, or other examination results judged by the clinician as abnormal with clinical significance (confirmed upon repeat assessment); OR presence of the following abnormal laboratory indicators: Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), total bilirubin, direct bilirubin, creatinine above the upper limit of normal (ULN); platelet count below the lower limit of normal (LLN); hyperkalemia, hypokalemia, hypercalcemia, or hypocalcemia judged by the investigator as abnormal and clinically significant; PT prolongation \> ULN + 3s, TT prolongation \> ULN + 3s, APTT prolongation \> ULN + 10s, INR \> 1.2, FIB \< 1.5 g/L or \> 4.0 g/L, D-Dimer above ULN.
• Screening ECG findings judged as abnormal with clinical significance. Resting heart rate not within the range of 50 to 100 beats per minute (exclusive of boundaries). QTcF interval \> 470 ms (QTcF = QT/(RR)\^0.33) or PR interval outside the range of 120 to 220 ms.
• Risk factors for Torsades de Pointes, or family history (first-degree relatives - biological parents, siblings, or children) of short QT syndrome, long QT syndrome, unexplained sudden death at a young age (≤40 years), drowning, or sudden infant death syndrome.
• Positive screening results for Hepatitis B surface antigen (HBsAg), Hepatitis C virus (HCV) antibody, Treponema pallidum specific antibody, or Human Immunodeficiency Virus (HIV) antibody.
• Average daily alcohol consumption exceeding 2 units in the 2 years prior to screening, or weekly alcohol consumption \>14 units (1 unit alcohol ≈ 360 ml beer or 45 ml 40% spirits or 150 ml wine); consumption of any alcohol-containing product within 24 hours prior to investigational product administration; or inability to stop alcohol consumption during the trial; or positive alcohol breath test.
• Average daily cigarette consumption \>5 in the 2 years prior to screening, or inability to stop using any tobacco products during the trial.
• Positive screening result for drug abuse, or history of drug abuse or use of narcotics within the past five years.
• Use of any prescription drugs, over-the-counter (OTC) drugs, Chinese herbal medicines, or health products within 2 weeks prior to screening and during screening, or within 5 half-lives of such drugs.
• Any surgery or trauma within 1 year prior to investigational product administration that may affect trial safety or drug disposition, and judged by the investigator to be of current clinical significance; OR planned surgery during the trial or within 7 days after trial completion.
• Difficulty with venous blood sampling, history of hematophobia or trypanophobia, or intolerance to indwelling venous catheter for blood sampling; OR history of phlebitis.
• Blood donation or blood loss \>200 ml within 3 months prior to screening, or receipt of blood transfusion or blood products within 4 weeks; OR plan to donate blood during the trial or within 3 months after trial completion.
• History of blood abnormalities or related diseases, bleeding tendency, bleeding disorders (hemophilia, intracranial hemorrhage, gastrointestinal bleeding, urinary tract bleeding, hemoptysis, vitreous hemorrhage, etc.); OR arterial puncture at a site difficult to compress for hemostasis within 1 week prior; history of aneurysm.

Sponsors & Collaborators

• Jiangsu Simcere Pharmaceutical Co., Ltd.: lead

Study Sites (1)

Qilu Hospital of Shandong University

Jinan, Shandong, 250100, China

Location

Study Officials

• yuguo chen

  Qilu Hospital of Shandong University

  PRINCIPAL INVESTIGATOR

• wei zhao

  Qilu Hospital of Shandong University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

zhibiao song

CONTACT

86-13641133681; songzhibiao@simcere.com

wei zhao

CONTACT

0531-82169023; hao4wei2@haotmail.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 26, 2025
• First Posted: January 15, 2026
• Study Start: January 13, 2026
• Primary Completion (Estimated): June 30, 2026
• Study Completion (Estimated): July 31, 2026
• Last Updated: January 15, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)